Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
XOPENEX is a levalbuterol hydrochloride solution administered via inhalation for the treatment of bronchospasm and reversible obstructive airway disease. As the active R-enantiomer of albuterol, levalbuterol is designed to provide faster symptom relief with potentially reduced tremor compared to racemic albuterol. It is positioned as a rescue inhaler for acute respiratory symptoms in asthma and COPD patients.
Declining revenue trajectory and modest claim volume signal contraction phase; commercial teams likely focused on defend-and-harvest strategies rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on XOPENEX offers limited growth opportunity and presents a career challenge in a declining, mature product with minimal job openings. This role suits professionals seeking stability in a defend-and-harvest environment or looking to build deep respiratory/rescue inhaler expertise in a commoditized market.
Worked on XOPENEX at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo